<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94118">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01921855</url>
  </required_header>
  <id_info>
    <org_study_id>13787</org_study_id>
    <secondary_id>2008-000117-29</secondary_id>
    <nct_id>NCT01921855</nct_id>
  </id_info>
  <brief_title>Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors</brief_title>
  <acronym>MATCHBOX</acronym>
  <official_title>A Phase I, Randomized, Double-blind, Placebo Controlled, Single Dose Escalation Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>South Africa: Medicines Control Council</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first in humans study of BAY86-6150  (B0189) in non-bleeding subjects with
      moderate or severe congenital hemophilia A or B with or without inhibitors. This is a
      randomized, double-blind, placebo-controlled, single-dose, dose escalation study. It is
      designed to investigate the safety, tolerability, potential immunogenicity, pharmacokinetic
      and pharmacodynamic profile of BAY86-6150 (B0189) and to determine a dose or range of doses
      to be examined in subsequent studies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to Day 50</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment, based on plasma concentration of BAY86-6150</measure>
    <time_frame>9 time points from pre-dosing on Day 1 up to 48 hours post-dosing</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic assessment, based on plasma hemostasis marker level</measure>
    <time_frame>9 time points from pre-dosing on Day 1 up to 48 hours post-dosing</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity assessment, based on anti-BAY86-6150 binding antibody levels</measure>
    <time_frame>3 time points from pre-dosing on Day 1 up to Day 50</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hemophilia A</condition>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>BAY Factor VII (6.5 µg/kg) / Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n = 4, randomized 3:1; 6.5 µg/kg BAY 86-6150 (B0189):Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY Factor VII (20 µg/kg) / Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n = 4, randomized 3:1; 20 µg/kg BAY 86-6150 (B0189):Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY Factor VII (50 µg/kg) / Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n = 4, randomized 3:1; 50 µg/kg BAY 86-6150 (B0189):Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY Factor VII (90 µg/kg) / Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n = 4, randomized 3:1; 90 µg/kg BAY 86-6150 (B0189):Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY Factor VII (BAY86-6150)</intervention_name>
    <description>BAY Factor VII (BAY86-6150), 6.5 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.</description>
    <arm_group_label>BAY Factor VII (6.5 µg/kg) / Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY Factor VII (BAY86-6150)</intervention_name>
    <description>BAY Factor VII (BAY86-6150), 20 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.</description>
    <arm_group_label>BAY Factor VII (20 µg/kg) / Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY Factor VII (BAY86-6150)</intervention_name>
    <description>BAY Factor VII (BAY86-6150), 50 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.</description>
    <arm_group_label>BAY Factor VII (50 µg/kg) / Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY Factor VII (BAY86-6150)</intervention_name>
    <description>BAY Factor VII (BAY86-6150), 90 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.</description>
    <arm_group_label>BAY Factor VII (90 µg/kg) / Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.</description>
    <arm_group_label>BAY Factor VII (6.5 µg/kg) / Placebo</arm_group_label>
    <arm_group_label>BAY Factor VII (20 µg/kg) / Placebo</arm_group_label>
    <arm_group_label>BAY Factor VII (50 µg/kg) / Placebo</arm_group_label>
    <arm_group_label>BAY Factor VII (90 µg/kg) / Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of moderate or severe congenital hemophilia A or B with or without inhibitors
             to Factor VIII (FVIII) or Factor IX (FIX)

          -  Male subjects 18-65 years of age inclusive

          -  Able to dismiss factor replacement therapy during the course of the study unless
             required for the treatment of an acute bleeding episode

          -  Written informed consent

          -  Willing and able to comply with the requirements of the protocol

          -  Have adequate venous access

          -  Willing to use an effective method of contraception until Day 30 of their study
             participation

        Exclusion Criteria:

          -  Received factor replacement therapy or treatment with any other procoagulant
             therapeutics, or any antifibrinolytic agents, including blood products, at anytime
             within 5 days prior to administration of investigational medicinal product (IMP)

          -  Planned administration of factor replacement therapy or treatment with any other
             procoagulant therapeutics or any antifibrinolytic agents, including blood products,
             at anytime during the study period

          -  Acute bleeding episode or any ongoing bleeding episode at any time within 7 days
             prior to administration IMP

          -  Clinically relevant coagulation disorder other than congenital hemophilia A or B

          -  History of angina or receiving treatment for angina

          -  History of coronary atherosclerotic disease, disseminated intravascular coagulopathy,
             or stage 2 hypertension defined as systolic blood pressure (SBP) &gt;/= 160 mmHg or
             diastolic blood pressure (DBP) &gt;/= 90 mmHg

          -  History of transient ischemic attack, stroke, myocardial infarction, coronary artery
             disease, congestive heart failure, or thromboembolic event

          -  Active infection on day of IMP administration or septicemia at any time within 30
             days prior to administration of IMP
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloemfontein</city>
        <state>Freestate</state>
        <zip>9300</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 9, 2013</lastchanged_date>
  <firstreceived_date>July 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
